Mechanisms of recurrence of Ta/T1 bladder cancer
- PMID: 20522307
- PMCID: PMC3182798
- DOI: 10.1308/003588410X12664192076935
Mechanisms of recurrence of Ta/T1 bladder cancer
Abstract
Introduction: Bladder cancer recurrence occurs via four mechanisms - incomplete resection, tumour cell re-implantation, growth of microscopic tumours, and new tumour formation. The first two mechanisms are influenced by clinicians before and immediately after resection; the remaining mechanisms have the potential to be influenced by chemopreventive agents. However, the relative importance and timing of these mechanisms is currently unknown. Our objective was to postulate the incidence and timing of these mechanisms by investigating the location of bladder cancer recurrences over time.
Patients and methods: The topographical locations of tumours and their recurrences were analysed retrospectively for 169 patients newly-diagnosed with Ta/T1 bladder cancer, with median follow-up of 33.8 months. Tumours were assigned to one or more of six bladder sectors, and time to recurrence and location of recurrences were recorded.
Results: Median time to first tumour recurrence was 40 months. Median times between subsequent recurrences were 6.6, 7.9, 8.0 and 6.6 months for recurrences 1 to 2, 2 to 3, 3 to 4, and 4 to 5, respectively. The risk of first tumour recurrence in any given bladder sector increased by nearly 4-fold if the primary tumour was resected from that sector (P < 0.001); this association was not significant for subsequent recurrences. The proportion of tumour recurrences in multiple bladder sectors increased from 13% for the first recurrence to 100% for recurrence seven onwards.
Conclusions: First tumour recurrence appears different to subsequent recurrences; incomplete resection and tumour cell reimplantation may dominate at this time-point. Only later does genuine new tumour formation appear to increase in importance. This has important implications for clinical trials, especially those involving chemopreventive agents.
Figures




Comment in
-
Re.: Mechanisms of recurrence of Ta/T1 bladder cancer.J Urol. 2011 May;185(5):1642. doi: 10.1016/j.juro.2011.01.072. Epub 2011 Mar 21. J Urol. 2011. PMID: 22088690 No abstract available.
Similar articles
-
Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.BJU Int. 2011 Oct;108(8 Pt 2):E297-303. doi: 10.1111/j.1464-410X.2011.10090.x. Epub 2011 Mar 17. BJU Int. 2011. PMID: 21414125 Clinical Trial.
-
Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.Scand J Urol Nephrol. 2008;42(5):417-21. doi: 10.1080/00365590802016302. Scand J Urol Nephrol. 2008. PMID: 18609266
-
A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years.Scand J Urol Nephrol. 2003;37(3):195-201. doi: 10.1080/00365590310008037. Scand J Urol Nephrol. 2003. PMID: 12775276
-
Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.Eur Urol. 2018 Jun;73(6):925-933. doi: 10.1016/j.eururo.2018.02.014. Epub 2018 Mar 6. Eur Urol. 2018. PMID: 29523366
-
[Histopathologic characteristics and clinical behavior of superficial bladder tumors].Orv Hetil. 1990 Feb 11;131(6):283-4, 287-9. Orv Hetil. 1990. PMID: 2406685 Review. Hungarian.
Cited by
-
The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis.BJU Int. 2021 Feb;127(2):143-152. doi: 10.1111/bju.15146. Epub 2020 Aug 12. BJU Int. 2021. PMID: 32564458 Free PMC article.
-
Hypermethylated TAGMe as a universal-cancer-only methylation marker and its application in diagnosis and recurrence monitoring of urothelial carcinoma.J Transl Med. 2024 Jul 2;22(1):608. doi: 10.1186/s12967-024-05420-3. J Transl Med. 2024. PMID: 38956589 Free PMC article.
-
Urinary DNA methylation-based risk stratification model to triage patients for repeat transurethral resection of bladder tumours.Clin Transl Med. 2024 Jan;14(1):e1549. doi: 10.1002/ctm2.1549. Clin Transl Med. 2024. PMID: 38251828 Free PMC article. No abstract available.
-
Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT.Health Technol Assess. 2024 Aug;28(42):1-65. doi: 10.3310/DEHT5407. Health Technol Assess. 2024. PMID: 39246267 Free PMC article. Clinical Trial.
-
Charlson-Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer.Cancers (Basel). 2023 Dec 8;15(24):5770. doi: 10.3390/cancers15245770. Cancers (Basel). 2023. PMID: 38136315 Free PMC article.
References
-
- Office for National Statistics. Report: Cancer incidence and mortality in the United Kingdom and constituent countries, 2003–05. Health Statistics Quarterly. 2008;40:1–91. - PubMed
-
- van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56:430–42. - PubMed
-
- Eble JN, Young RH. Carcinoma of the urinary bladder: a review of its diverse morphology. Semin Diagn Pathol. 1997;14:98–108. - PubMed
-
- Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackerman R, Vögeli T. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol. 2003;170:433–7. - PubMed
-
- Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–77. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical